Skip to main content
Top
Published in: Journal of Neurology 7/2007

Open Access 01-07-2007 | ORIGINAL COMMUNICATION

Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis

Authors: P. Sanchez-Juan, MD, R. Sánchez-Valle, MD, A. Green, PhD, A. Ladogana, MD, N. Cuadrado-Corrales, PhD, E. Mitrová, MD, K. Stoeck, MD, T. Sklaviadis, PhD, J. Kulczycki, PhD, K. Hess, MD, A. Krasnianski, M. Equestre, MD, D. Slivarichová, MSc, A. Saiz, MD, M. Calero, PhD, M. Pocchiari, PhD, R. Knight, FRCP(E), C. M. van Duijn, PhD, I. Zerr, MD

Published in: Journal of Neurology | Issue 7/2007

Login to get access

Abstract

Background

The analysis of markers in the cerebrospinal fluid (CSF) is useful in the diagnosis of sporadic Creutzfeldt-Jakob disease (sCJD). However, the time at which the study of these markers is most sensitive remains controversal.

Objective

To assess the influence of time of sampling on the value of CSF tests in the diagnosis of sCJD.

Method

In the framework of a multinational European study, we studied the results of 14-3-3, S100b, neurone specific enolase (NSE) and tau protein in 833 CSF samples from sCJD patients at different stages of disease and in 66 sequentially repeated lumbar punctures (LP).

Results

14-3-3 and tau protein tended to increase in sensitivity from onset (88%, 81%) to the advanced stage (91%, 90%). This was significant only in the methionine-valine (MV) heterozygous group of patients at codon 129. The absolute levels of S100b (p < 0.05), NSE and tau protein increased in the last stage of disease. High levels of tau protein, NSE and S100b were associated with shorter survival times (p < 0.01). Sixty-six sCJD patients underwent repeated LP. These sCJD patients were younger, had longer disease durations and were more frequently MV at codon 129 (p < 0.001) than the whole group. 14-3-3 sensitivity increased from 64% to 82% in the second LP (p = 0.025) and 88% sCJD patients had at least one positive result.

Conclusions

Sensitivity and absolute levels of CJD markers increased with disease progression and were modulated by the codon 129 genotype. Early negative results should be inter-preted with caution, especially in young patients or those who are MV at codon 129.
Literature
1.
go back to reference Beaudry P, Cohen P, Brandel JP, et al. (1999) 14-3-3 protein, neuron-specific enolase, and S100b protein in cerebrospinal fluid of patients with Creutzfeldt- Jakob disease. Dement Geriatr Cogn Disord 10(1):40–6CrossRefPubMed Beaudry P, Cohen P, Brandel JP, et al. (1999) 14-3-3 protein, neuron-specific enolase, and S100b protein in cerebrospinal fluid of patients with Creutzfeldt- Jakob disease. Dement Geriatr Cogn Disord 10(1):40–6CrossRefPubMed
2.
go back to reference Brandel JP, Peoc’h K, Beaudry P, et al. (2001) 14-3-3 protein cerebrospinal fluid detection in human growth hormone- treated Creutzfeldt-Jakob disease patients. Ann Neurol 49(2):257–60CrossRefPubMed Brandel JP, Peoc’h K, Beaudry P, et al. (2001) 14-3-3 protein cerebrospinal fluid detection in human growth hormone- treated Creutzfeldt-Jakob disease patients. Ann Neurol 49(2):257–60CrossRefPubMed
3.
go back to reference Giraud P, Biacabe A-G, Chazot G, et al. (2002) Increased detection of 14-3-3 protein in Cerebrospinal fluid in Sporadic Creutzfeldt-Jakob disease during the disease course. Eur Neurol 48:218–221CrossRefPubMed Giraud P, Biacabe A-G, Chazot G, et al. (2002) Increased detection of 14-3-3 protein in Cerebrospinal fluid in Sporadic Creutzfeldt-Jakob disease during the disease course. Eur Neurol 48:218–221CrossRefPubMed
4.
go back to reference Green AJE, Keir G, Thompson EJ (1997) A specific and sensitive ELISA for measuring S100b in the cerebrospinal fluid. J Immmunol Methods 205:35–41CrossRef Green AJE, Keir G, Thompson EJ (1997) A specific and sensitive ELISA for measuring S100b in the cerebrospinal fluid. J Immmunol Methods 205:35–41CrossRef
5.
go back to reference Jimi T, Wakayama Y, Shibuya S, et al. (1992) High levels of nervous systemspecific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 211:37–46CrossRefPubMed Jimi T, Wakayama Y, Shibuya S, et al. (1992) High levels of nervous systemspecific proteins in cerebrospinal fluid in patients with early stage Creutzfeldt-Jakob disease. Clin Chim Acta 211:37–46CrossRefPubMed
6.
go back to reference Kropp S, Zerr I, Schulz-Schaeffer WJ, et al. (1999) Increase of neuron-specific enolase in patients with Creutzfeldt- Jakob disease. Neurosc Lett 261(1–2):124–6CrossRef Kropp S, Zerr I, Schulz-Schaeffer WJ, et al. (1999) Increase of neuron-specific enolase in patients with Creutzfeldt- Jakob disease. Neurosc Lett 261(1–2):124–6CrossRef
7.
go back to reference Mollenhauer B, Serafin S, Zerr I, et al. (2003) Diagnostic problems during late course in Creutzfeldt-Jakob disease. J Neurol 250:629–630CrossRefPubMed Mollenhauer B, Serafin S, Zerr I, et al. (2003) Diagnostic problems during late course in Creutzfeldt-Jakob disease. J Neurol 250:629–630CrossRefPubMed
8.
go back to reference Otto M, Wiltfang J, Cepek L, et al. (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58:192–197PubMed Otto M, Wiltfang J, Cepek L, et al. (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58:192–197PubMed
9.
go back to reference Sánchez-Juan P, Green A, Ladogana A, et al. (2006) CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67(4):637–643CrossRefPubMed Sánchez-Juan P, Green A, Ladogana A, et al. (2006) CSF tests in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 67(4):637–643CrossRefPubMed
10.
go back to reference Van Everbroeck B, Green AJ, Vanmechelen E, et al. (2002) Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatr 73(1):79–81CrossRefPubMed Van Everbroeck B, Green AJ, Vanmechelen E, et al. (2002) Phosphorylated tau in cerebrospinal fluid as a marker for Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatr 73(1):79–81CrossRefPubMed
11.
go back to reference Van Everbroeck B, Quolin S, Boons J, et al. (2003) A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 74:1210–1214CrossRefPubMed Van Everbroeck B, Quolin S, Boons J, et al. (2003) A prospective study of CSF markers in 250 patients with possible Creutzfeldt-Jakob disease. J Neurol Neurosurg Psychiatry 74:1210–1214CrossRefPubMed
12.
go back to reference WHO. Human transmissible spongiform encephalopathies (1998) Wkly Epidemiol Rec 73:361–72 WHO. Human transmissible spongiform encephalopathies (1998) Wkly Epidemiol Rec 73:361–72
13.
go back to reference Zerr I, Bodemer M, Räcker S, et al. (1995) Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 345:1609–1610CrossRefPubMed Zerr I, Bodemer M, Räcker S, et al. (1995) Cerebrospinal fluid concentration of neuron-specific enolase in diagnosis of Creutzfeldt-Jakob disease. Lancet 345:1609–1610CrossRefPubMed
14.
go back to reference Zerr I, Pocchiari M, Collins S, et al. (2000) Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 55:811–815PubMed Zerr I, Pocchiari M, Collins S, et al. (2000) Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 55:811–815PubMed
Metadata
Title
Influence of timing on CSF tests value for Creutzfeldt-Jakob disease diagnosis
Authors
P. Sanchez-Juan, MD
R. Sánchez-Valle, MD
A. Green, PhD
A. Ladogana, MD
N. Cuadrado-Corrales, PhD
E. Mitrová, MD
K. Stoeck, MD
T. Sklaviadis, PhD
J. Kulczycki, PhD
K. Hess, MD
A. Krasnianski
M. Equestre, MD
D. Slivarichová, MSc
A. Saiz, MD
M. Calero, PhD
M. Pocchiari, PhD
R. Knight, FRCP(E)
C. M. van Duijn, PhD
I. Zerr, MD
Publication date
01-07-2007
Publisher
Steinkopff-Verlag
Published in
Journal of Neurology / Issue 7/2007
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-006-0472-9

Other articles of this Issue 7/2007

Journal of Neurology 7/2007 Go to the issue